TY - JOUR
T1 - Long-Term Arrhythmic Risk Assessment in Biopsy-Proven Myocarditis
AU - Pelargonio, Gemma
AU - Pinnacchio, Gaetano
AU - Narducci, Maria Lucia
AU - Pieroni, Maurizio
AU - Perna, Francesco
AU - Bencardino, Gianluigi
AU - Comerci, Gianluca
AU - Dello Russo, Antonio
AU - Casella, Michela
AU - Bartoletti, Silvia
AU - Russo, Eleonora
AU - Crea, Filippo
PY - 2020
Y1 - 2020
N2 - Objectives: This study sought to assess long-term arrhythmic risk in patients with myocarditis who received an implantable cardioverter-defibrillator (ICD). Background: The arrhythmic risk of patients with myocarditis overtime remains poorly known. Methods: The study enrolled 56 patients with biopsy-proven myocarditis who received an ICD for either primary (57%) or secondary prevention (43%) according to current guidelines. Clinical characteristics, biopsy findings, electrophysiological data from endocardial 3-dimensional electroanatomic voltage mapping, and device interrogation data were analyzed to detect arrhythmic events overtime. Coronary angiography excluded significant coronary artery disease in all patients. Results: At a mean follow-up of 74 ± 60 months (median 65 months), 25 (45%) patients had major ventricular arrhythmias treated by ICD intervention (76% being terminated by ICD shock and 24% by antitachyarrhythmia burst pacing). At multivariable analysis, the presence of sustained ventricular tachycardia on admission (hazard ratio: 13.0; 95% confidence interval: 2.0 to 35.0; p = 0.032) and the extension of the areas of low potentials at the bipolar endocardial mapping (hazard ratio: 1.19; 95% confidence interval: 1.04 to 1.37; p = 0.013) were the only independent predictors of appropriate ICD interventions. A cutoff value of 10% of abnormal bipolar area at electroanatomical ventricular mapping discriminated patients with appropriate ICD interventions with a sensitivity of 89% and a specificity of 85%. Conclusions: The study demonstrates that the prevalence of life-threatening ventricular arrhythmias in patients with myocarditis receiving an ICD according to current guidelines is high and the arrhythmic risk persists late overtime. Electroanatomical ventricular mapping may be a useful tool to identify patients at greater arrhythmic risk.
AB - Objectives: This study sought to assess long-term arrhythmic risk in patients with myocarditis who received an implantable cardioverter-defibrillator (ICD). Background: The arrhythmic risk of patients with myocarditis overtime remains poorly known. Methods: The study enrolled 56 patients with biopsy-proven myocarditis who received an ICD for either primary (57%) or secondary prevention (43%) according to current guidelines. Clinical characteristics, biopsy findings, electrophysiological data from endocardial 3-dimensional electroanatomic voltage mapping, and device interrogation data were analyzed to detect arrhythmic events overtime. Coronary angiography excluded significant coronary artery disease in all patients. Results: At a mean follow-up of 74 ± 60 months (median 65 months), 25 (45%) patients had major ventricular arrhythmias treated by ICD intervention (76% being terminated by ICD shock and 24% by antitachyarrhythmia burst pacing). At multivariable analysis, the presence of sustained ventricular tachycardia on admission (hazard ratio: 13.0; 95% confidence interval: 2.0 to 35.0; p = 0.032) and the extension of the areas of low potentials at the bipolar endocardial mapping (hazard ratio: 1.19; 95% confidence interval: 1.04 to 1.37; p = 0.013) were the only independent predictors of appropriate ICD interventions. A cutoff value of 10% of abnormal bipolar area at electroanatomical ventricular mapping discriminated patients with appropriate ICD interventions with a sensitivity of 89% and a specificity of 85%. Conclusions: The study demonstrates that the prevalence of life-threatening ventricular arrhythmias in patients with myocarditis receiving an ICD according to current guidelines is high and the arrhythmic risk persists late overtime. Electroanatomical ventricular mapping may be a useful tool to identify patients at greater arrhythmic risk.
KW - implantable cardioverter-defibrillator
KW - innovative biotechnology
KW - myocarditis
KW - personalized medicine
KW - sudden cardiac death
KW - ventricular arrhythmias
KW - implantable cardioverter-defibrillator
KW - innovative biotechnology
KW - myocarditis
KW - personalized medicine
KW - sudden cardiac death
KW - ventricular arrhythmias
UR - http://hdl.handle.net/10807/166650
U2 - 10.1016/j.jacep.2019.12.010
DO - 10.1016/j.jacep.2019.12.010
M3 - Article
SN - 2405-500X
VL - 6
SP - 574
EP - 582
JO - JACC. CLINICAL ELECTROPHYSIOLOGY
JF - JACC. CLINICAL ELECTROPHYSIOLOGY
ER -